Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$1.8 million.

  • Centessa Pharmaceuticals' Other Non Operating Income fell 14939.96% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.6 million, marking a year-over-year decrease of 249272.99%. This contributed to the annual value of -$34.1 million for FY2024, which is 52816.88% down from last year.
  • Centessa Pharmaceuticals' Other Non Operating Income amounted to -$1.8 million in Q3 2025, which was down 14939.96% from $3.6 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Other Non Operating Income high stood at $5.4 million for Q2 2022, and its period low was -$36.4 million during Q4 2024.
  • For the 4-year period, Centessa Pharmaceuticals' Other Non Operating Income averaged around -$2.3 million, with its median value being -$878000.0 (2023).
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Other Non Operating Income plummeted by 404328.02% in 2024, and later surged by 223246.75% in 2025.
  • Centessa Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$70000.0 in 2022, then plummeted by 1154.29% to -$878000.0 in 2023, then crashed by 4043.28% to -$36.4 million in 2024, then surged by 95.02% to -$1.8 million in 2025.
  • Its Other Non Operating Income was -$1.8 million in Q3 2025, compared to $3.6 million in Q2 2025 and $1.0 million in Q1 2025.